Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

NCT05187338 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Liver Cancer
Colorectal Cancer
Pancreas Cancer
Ovary Cancer
Head and Neck Cancer
Breast Cancer
Gastric Cancer
Cervical Cancer
Esophageal Cancer
Sarcoma

Interventions

DRUG: ipilimumab +pembrolizumab +durvalumab

Sponsor

Second Affiliated Hospital of Guangzhou Medical University